A molecular computational model improves the preoperative diagnosis of thyroid nodules

BackgroundThyroid nodules with indeterminate cytological features on fine needle aspiration (FNA) cytology have a 20% risk of thyroid cancer. The aim of the current study was to determine the diagnostic utility of an 8-gene assay to distinguish benign from malignant thyroid neoplasm.MethodsThe mRNA expression level of 9 genes (KIT, SYNGR2, C21orf4, Hs.296031, DDI2, CDH1, LSM7, TC1, NATH) was analysed by quantitative PCR (q-PCR) in 93 FNA cytological samples. To evaluate the diagnostic utility of all the genes analysed, we assessed the area under the curve (AUC) for each gene individually and in combination. BRAF exon 15 status was determined by pyrosequencing. An 8-gene computational model (Neural Network Bayesian Classifier) was built and a multiple-variable analysis was then performed to assess the correlation between the markers.ResultsThe AUC for each significant marker ranged between 0.625 and 0.900, thus all the significant markers, alone and in combination, can be used to distinguish between malignant and benign FNA samples. The classifier made up of KIT, CDH1, LSM7, C21orf4, DDI2, TC1, Hs.296031 and BRAF had a predictive power of 88.8%. It proved to be useful for risk stratification of the most critical cytological group of the indeterminate lesions for which there is the greatest need of accurate diagnostic markers.ConclusionThe genetic classification obtained with this model is highly accurate at differentiating malignant from benign thyroid lesions and might be a useful adjunct in the preoperative management of patients with thyroid nodules.

[1]  E. Mazzaferri,et al.  Thyroid cancer in thyroid nodules: finding a needle in the haystack. , 1992, The American journal of medicine.

[2]  R. Moon,et al.  TC1 (C8orf4) enhances the Wnt/beta-catenin pathway by relieving antagonistic activity of Chibby. , 2006, Cancer research.

[3]  A. Gelfand,et al.  Predicting the cumulative risk of false-positive mammograms. , 2000, Journal of the National Cancer Institute.

[4]  S. Libutti,et al.  Using gene expression profiling to differentiate benign versus malignant thyroid tumors. , 2004, Cancer research.

[5]  D. Clark,et al.  Beyond the suspicious thyroid fine needle aspirate. A review. , 2003, Acta cytologica.

[6]  A. Öberg,et al.  Biomarker selection for detection of occult tumour cells in lymph nodes of colorectal cancer patients using real-time quantitative RT–PCR , 2006, British Journal of Cancer.

[7]  Z. Baloch,et al.  The quest for a magic tumor marker: continuing saga in the diagnosis of the follicular lesions of thyroid. , 2002, American journal of clinical pathology.

[8]  F H Edwards,et al.  1988: use of a Bayesian statistical model for risk assessment in coronary artery surgery. Updated in 1995. , 1995, The Annals of thoracic surgery.

[9]  B. Roe,et al.  Characterization of the human synaptogyrin gene family , 1998, Human Genetics.

[10]  D. Ross.  Nonpalpable thyroid nodules--managing an epidemic. , 2002, The Journal of clinical endocrinology and metabolism.

[11]  J. Ross,et al.  Tumorigenesis and Neoplastic Progression Snail Family Transcription Factors Are Implicated in Thyroid Carcinogenesis , 2007 .

[12]  V. Fazio,et al.  Assessment of Operative Risk in Colorectal Cancer Surgery: The Cleveland Clinic Foundation Colorectal Cancer Model , 2004, Diseases of the colon and rectum.

[13]  N. Tommerup,et al.  Global gene expression analysis in fetal mouse ovaries with and without meiosis and comparison of selected genes with meiosis in the testis , 2007, Cell and Tissue Research.

[14]  Daniel Birnbaum,et al.  Carcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulators , 2002, Oncogene.

[15]  L. Young,et al.  Cloning of TC-1 (C8orf4), a novel gene found to be overexpressed in thyroid cancer. , 2000, Genomics.

[16]  R. Bellamy,et al.  Use of artificial intelligence for the preoperative diagnosis of pulmonary lesions. , 1989, The Annals of thoracic surgery.

[17]  Ross D. Shachter,et al.  Bayesian network to predict breast cancer risk of mammographic microcalcifications and reduce number of benign biopsy results: initial experience. , 2006, Radiology.

[18]  D. Sargent,et al.  Comparison of artificial neural networks with other statistical approaches , 2001, Cancer.

[19]  D. Madigan,et al.  Bayesian logistic injury severity score: a method for predicting mortality using international classification of disease-9 codes. , 2008, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[20]  E. D. de Vries,et al.  Detection of micrometastatic breast cancer by means of real time quantitative RT‐PCR and immunostaining in perioperative blood samples and sentinel nodes , 2003, International journal of cancer.

[21]  F H Edwards,et al.  Use of a Bayesian statistical model for risk assessment in coronary artery surgery. , 1988, The Annals of thoracic surgery.

[22]  Gerhard Christofori,et al.  Cell adhesion and signalling by cadherins and Ig-CAMs in cancer , 2004, Nature Reviews Cancer.

[23]  P. Ladenson,et al.  Quantitative assessment of promoter methylation profiles in thyroid neoplasms. , 2005, The Journal of clinical endocrinology and metabolism.

[24]  Simone Brabletz,et al.  E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer , 2009, Cancer and Metastasis Reviews.

[25]  G. Bevilacqua,et al.  c-KIT receptor expression is strictly associated with the biological behaviour of thyroid nodules , 2012, Journal of Translational Medicine.

[26]  A. Visel,et al.  Transmembrane protein 50b (C21orf4), a candidate for Down syndrome neurophenotypes, encodes an intracellular membrane protein expressed in the rodent brain , 2008, Neuroscience.

[27]  P. Barbini,et al.  A multivariate Bayesian model for assessing morbidity after coronary artery surgery , 2006, Critical care.

[28]  L. Young,et al.  TC-1 is a novel tumorigenic and natively disordered protein associated with thyroid cancer. , 2004, Cancer research.

[29]  Dominik Aronsky,et al.  Using Bayesian Networks to Predict Survival of Liver Transplant Patients , 2005, AMIA.

[30]  D. Liberles,et al.  Characterization of hARD2, a processed hARD1 gene duplicate, encoding a human protein N-α-acetyltransferase , 2006, BMC Biochemistry.

[31]  Jean D. Beggs,et al.  Yeast Sm-like proteins function in mRNA decapping and decay , 2000, Nature.

[32]  L. Akslen,et al.  NATH, a novel gene overexpressed in papillary thyroid carcinomas , 2002, Oncogene.

[33]  J Wakefield,et al.  An application of Bayesian population pharmacokinetic/pharmacodynamic models to dose recommendation. , 1995, Statistics in medicine.

[34]  D. Ginzinger.  Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. , 2002, Experimental hematology.

[35]  S. Alahari,et al.  Molecular mechanisms controlling E-cadherin expression in breast cancer. , 2009, Biochemical and biophysical research communications.

[36]  K. Rodvold,et al.  Bayesian Forecasting of Serum Gentamicin Concentrations in Intensive Care Patients , 1990, Clinical pharmacokinetics.

[37]  Q. Duh,et al.  Does the 3‐gene diagnostic assay accurately distinguish benign from malignant thyroid neoplasms? , 2008, Cancer.

[38]  S. Libutti,et al.  A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression. , 2005, Surgery.

[39]  P. Mohan,et al.  MDRD-Estimated GFR at One Year Post-Renal Transplant Is a Predictor of Long-Term Graft Function , 2008, Renal failure.